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A ccording to the 2017 World Health Organization classification,  low-grade B-cell lymphomas 
(LGBCLs) comprise follicular lymphoma (FL),  mar-
ginal zone lymphoma (MZL),  small lymphocytic lym-
phoma/chronic lymphocytic leukemia (SLL/CLL),  
lymphoplasmacytic lymphoma/Waldenström’s macro-
globulinemia (LPL/WM),  and mantle cell lymphoma 
(MCL) [1].  This classification has been widely used in 
various clinical trials,  and bendamustine is now com-
monly used as a treatment option for these diseases.
Bendamustine hydrochloride was designed in East 
Germany in the 1960s as a drug having both the nitro-
gen-mustard structure of an alkylator and a purine ana-
logue-like structure.  Bendamustine damages the double 
strands of DNA more strongly and more quickly than 
other alkylators.  The DNA damage caused by benda-
mustine is not affected by the repair mechanisms 
induced by other DNA-damaging alkylators.  Therefore,  
bendamustine has no cross-resistance with other alkyla-
tors [2-4].
A phase II clinical study evaluating the efficacy and 
safety of bendamustine plus rituximab (B-R) therapy for 
relapsed or refractory (r/r) LGBCL and MCL was 
reported in 2008.  The overall response rate (ORR) and 
median progression-free survival (PFS) were 92% and 
23 months,  respectively.  The treatment was well toler-
ated,  with the primary adverse event being myelosup-
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pression; grade 3/4 neutropenia and leukopenia were 
observed in 36% and 30% of the patients,  respectively 
[5].  Japan approved the use of bendamustine for r/r 
LGBCL and MCL in 2010.  B-R therapy has been widely 
used since then,  but there is a lack of clinical data from 
Japanese patients treated with B-R therapy.  Therefore,  
we retrospectively evaluated the efficacy and safety of 
B-R therapy for r/r LGBCL and MCL patients at our 
clinical practice.
Patients and Methods
Patients. We registered 42 patients who had 
received B-R therapy for r/r LGBCL and MCL from 
September 2011 to March 2019 at the Department of 
Hematology,  National Hospital Organization Okayama 
Medical Center.  This study was conducted in accor-
dance with the Declaration of Helsinki and Ethical 
Guidelines for Medical and Health Research Involving 
Human Subjects and was approved by the local ethics 
committee of the National Hospital Organization 
Okayama Medical Center (No. 2019-247).
Treatment. Patients received B-R therapy [intra-
venous (IV) rituximab 375 mg/m2 on day 1 and IV 
bendamustine 90 mg/m2 on days 2 and 3,  administered 
every 28 days for up to 6 cycles].  The dose of benda-
mustine and schedule of B-R therapy were modified 
according to the discretion of the attending physician.  
Antibiotic (sulfamethoxazole: 80 mg/day,  trimetho-
prim: 400 mg/day) and antiviral (acyclovir: 200- 
400 mg/day) prophylaxes were routinely administered 
to all patients.  The dose of these drugs was adjusted 
according the patients’ renal function.
Outcome assessment and statistical analysis.
Response was defined according to the guidelines estab-
lished by an international workshop to standardize 
response criteria for non-Hodgkin’s lymphoma [6].  PFS 
was defined as the time from the start of treatment to 
disease progression or death.  Overall survival (OS) was 
defined as the time from the start of treatment to death.  
The severity of adverse events (AEs) was graded accord-
ing to the Common Terminology Criteria for Adverse 
Events,  version 4.0.  Relative dose intensity (RDI) of 
bendamustine was defined as the ratio of actual admin-
istered dose per protocol dose per unit time.  PFS and 
OS were estimated using the Kaplan–Meier method and 
were compared between groups by log-rank test.  Cox 
proportional hazards regression models were used to 
assess whether patient characteristics at treatment were 
predictive of PFS and OS.  The ORR was compared 
between the 2 groups using Fisher’s exact test.  All tests 
were two-sided and the level of statistical significance 
for all analyses was defined as p < 0.05.  Statistical analy-
sis was performed using EZR software (ver. 1.35) [7].
Results
Patients characteristics. The patient characteris-
tics are summarized in Table 1.  The histologic subtypes 
were FL (n = 29,  70%),  MZL (n = 6,  14%),  SLL (n = 1,  
2%),  LPL (n=1,  2%),  and MCL (n= 5,  12%).  Rebiopsy 
was not conducted because there were no patients sus-
pected of histological transformation.  The median 
patient age was 78.5 years (range,  41 to 87),  the sex ratio 
was 24 : 18 (male: female),  and 90% of the patients were 
diagnosed as being at an advanced stage.  Bulky mass 
lesions (> 7 cm) were found in 4 patients,  extranodal 
lesions were found in 10 patients,  and high lactate 
dehydrogenase (LDH) levels (> 240 IU/l) were found in 
30 patients.  In 83% (n = 35) of patients,  B-R therapy 
was second line.  Four patients were considered refrac-
tory to the previous therapy.  Most patients had received 
rituximab monotherapy or rituximab combination che-
motherapy as the last therapy prior to the B-R regimen.  
Two patients had been administered rituximab mainte-
nance therapy.  However,  none of our patients was 
treated with rituximab maintenance therapy after B-R 
therapy.  The median number of cycles of B-R therapy 
was 4 (range,  1 to 6).  The total number of cycles of B-R 
therapy administered was 196.  The number of patients 
who completed each cycle and the median interval days 
per cycle are detailed in Table 1.
Efficacy. The ORR,  complete response and com-
plete response unconfirmed (CR/CRu) rate and partial 
response (PR) rate were 93%,  62%,  and 31%,  respec-
tively (Table 2).  For LGBCL,  the ORR,  CR/CRu rate,  
and PR rate were 92%,  65%,  and 27%,  respectively.  
For MCL,  the ORR,  CR/CRu rate,  and PR rate were 
100%,  40%,  and 60%,  respectively.  With a median 
follow up of 53 months (range,  2.5-94),  the median 
PFS and OS were 39.5 months (95% confidence interval 
[CI],  24 to “not reached” [NR]) and 80 months (95% 
CI,  60.7 to NR),  respectively (Fig. 1).  In MCL,  the 
median PFS and OS were 39 (95% CI,  20.7 to NR) and 
47 months (95% CI,  22 to NR),  respectively.  The 10 
factors which could have influenced PFS－namely age,  
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Table 1　 Patient characteristics
No. of patients 42
Median age (range) 78.5 (41 to 87)
Male/Female 24/18
Histologic subtypes






















Median months from initial diagnosis to start of B-R therapy (range) 92.5 (3 to 180)
Median no. of prior regimens (range) 1 (1 to 3)
Prior regimens
　Rituximab monotherapy 21
　Rituximab + chemotherapy 23
　Other 6
Last regimen before B-R therapy
　Rituximab monotherapy 20




Median no. of cycles treated with B-R therapy (range) 4 (1 to 6)
Total no. of cycles treated with B-R therapy 196
No. of patients who completed the cycle (%)
　Cycle 1 42 (100)
　Cycle 2 41 (98)
　Cycle 3 34 (81)
　Cycle 4 33 (79)
　Cycle 5 25 (60)
　Cycle 6 21 (50)
Median interval days per cycle (range)
　Cycles 1 to 2 35 (28 to 267)
　Cycles 2 to 3 34 (28 to 98)
　Cycles 3 to 4 36 (28 to 77)
　Cycles 4 to 5 36 (28 to 103)
　Cycles 5 to 6 35 (28 to 90)
Median RDI (%) of bendamustine (range) 64.4 (23.5 to 100)
B,  bendamustine; R,  rituximab; LDH,  lactate dehydrogenase; RDI,  relative dose intensity.
sex,  histology,  LDH,  extranodal lesions,  bulky mass,  
time from diagnosis to initiation of B-R therapy,  regi-
men before B-R therapy,  cumulative dose of benda-
mustine,  and RDI of bendamustine－were analyzed 
using the log-rank test.  The median values of cumula-
tive dose of bendamustine and RDI of bendamustine 
were adopted as cut-offs.  High LDH (95% CI,  3.02 to 
NR,  p < 0.05),  extranodal lesions ≥ 1 (95% CI,  7.55 to 
39.32,  p < 0.05),  and cumulative dose of bendamustine 
< 720 mg/m2 (95% CI,  3.02 to 25.26,  p < 0.05) had sig-
nificantly inferior PFS in the log-rank test (Table 3).  
These 3 factors were subjected to Cox proportional haz-
ards regression analysis.  High LDH and cumulative 
dose of bendamustine < 720 mg/m2 had significantly 
inferior PFS (Table 4).  Furthermore,  high LDH and 
cumulative dose of bendamustine < 720 mg/m2 had sig-
nificantly inferior OS in the log-rank test and Cox pro-
portional hazards regression models (Tables 3 , 4).  The 
patient characteristics for the cumulative bendamustine 
doses groups ≥ 720 mg/m2 and < 720 mg/m2 are shown 
in Table 5.  There were no significant differences in 
patient characteristics between these 2 groups.  The rea-
sons for receiving a cumulative dose of bendamustine 
< 720 mg/m2 were prolonged neutropenia (n = 5,  42%),  
patient request (n = 2,  17%),  disease progression (n = 2,  
17%),  and other (n = 3,  25%); these events were not 
related to non-hematological AEs.  The ORR was sig-
nificantly better in the cumulative bendamustine dose 
≥ 720 mg/m2 group than in the < 720 mg/m2 group 
(100% vs. 75%,  p = 0.02).  However,  the CR/CRu rate 
was not significantly different between the 2 groups 
(Table 6).  The RDI was not significantly related to PFS,  
OS,  and ORR.  The follicular lymphoma international 
prognostic index (FLIPI) (low vs.  intermediate vs.  high 
risk) [8] was significantly associated with the PFS 
(p < 0.01,  log-rank analysis) but not with the OS 
(p = 0.077) in patients with FL (n = 29).
Safety. The AEs of B-R therapy are shown in 
Table 7.  The most frequently observed severe hemato-
logical AEs (grade 3/4) were neutropenia (n = 23,  55%) 
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Table 2　 Response with respect to pathological subtype
n
Response,  n (%)
ORR CR/CRu PR SD PD
All 42 39 (93) 26 (62) 13 (31) 1 (2) 2 (5)
Pathological subtype
　Low grade B-cell lymphoma 37 34 (92) 24 (65) 10 (27) 1 (3) 2 (5)
　Mantle cell lymphoma 5 5 (100) 2 (40) 3 (60) 0 (0) 0 (0)
ORR,  overall response rate; CR,  complete response; CRu,  complete response unconfirmed; PR,  partial response; SD,  stable disease;  
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Median OS 80 months (95% CI 60.7 to NR)
Fig. 1　 Kaplan‒Meier curve of progression-free survival (A) and overall survival (B) in all patients (n=42) receiving B-R therapy.
PFS,  progression-free survival; OS,  overall survival; NR,  not reached; CI,  confidence interval; B,  bendamustine; R,  rituximab.
and lymphopenia (n = 29,  69%).  Granulocyte-colony 
stimulating factor (G-CSF) was administered to 36 
patients (85%).  Grade 3/4 anemia (n = 2,  5%) and 
thrombocytopenia (n = 3,  7%) were rarely found.  The 
most frequently observed non-hematological AEs were 
nausea (71%),  constipation (52%),  fatigue (38%),  rash 
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95% CI P value
Age
　≥75 14 25.2 14.09 to NR 0.17 80.2 14.29 to NR 0.53
　<75 28 54.8 24.64 to NR NR 67.22 to NR
Sex
　Male 24 39.3 21.58 to NR 0.57 83.7 47.87 to NR 0.92
　Female 18 NR 17.83 to NR 80.7 67.22 to NR
Histology
　FL 29 NR 24.64 to NR 0.14 80.7 67.22 to NR 0.62
　Others 13 37.9 14.09 to NR 83.7 17.84 to NR
LDH (IU/L)
　>240 12 20.7 3.02 to NR <0.05 20.7 8.74 to NR <0.05
　≤240 30 54.8 25.26 to NR 83.7 72.28 to NR
ENLs
　Yes 10 24.6 7.35 to 39.32 <0.05 80.7 14.29 to NR 0.17
　No 32 NR 25.26 to NR NR 67.22 to NR
Bulky mass (>7 cm)
　Yes 4 21.1 20.92 to NR 0.14 72.3 NR to NR 0.99
　No 38 54.8 24.64 to NR 83.7 67.22 to NR
Years from initial diagnosis to start 
of B-R
　≥2 20 NR 20.73 to NR 0.48 NR 47.87 to NR 0.36
　<2 22 37.9 21.12 to NR 80.7 54.83 to NR
Last regimen before B-R
　R monotherapy 21 NR 20.17 to NR 0.93 NR 28.8 to NR 0.67
　R + CT 21 39.3 24.64 to NR 80.7 54.83 to NR
Cumulative dose of bendamustine
　≥720 mg/m2 30 NR 37.94 to NR <0.05 83.7 67.22 to NR <0.05
　<720 mg/m2 12 20.7 3.02 to 25.26 72.3 8.74 to NR
RDI of bendamustine
　≥64.4% 21 42 24.64 to NR 0.469 NR 67.21 to NR 0.45
　<64.4% 21 29 20.1 to NR 80.2 20.7 to NR
PFS,  progression-free survival; CI,  confidence interval; NR,  not reached; OS,  overall survival; FL,  follicular lymphoma; LDH,  lactate 
dehydrogenase; ENL,  extranodal lesion; R,  rituximab; CT,  chemotherapy; RDI,  relative dose intensity.
Table 4　 Factors influencing survival (Cox proportional hazards regression analysis)
PFS OS
HR 95% CI P value HR 95% CI P value
LDH (>240 IU/L vs. ≤240 IU/L) 2.80 1.07 to 7.32 <0.05 3.31 1.05 to 10.43 <0.05
ENLs ≥1 (yes vs. no) 2.45 0.90 to 6.71 0.08 NE NE NE
Cumulative dose of bendamustine 
(<720 mg/m2 vs. ≥720 mg/m2) 6.70 2.20 to 20.45 <0.05 11.28 2.62 to 48.63 <0.05
PFS,  progression-free survival; OS,  overall survival; HR,  hazard ratio; CI,  confidence interval; ENL,  extranodal lesion; NE,  not evaluated.
(19%),  and infusion-related reactions (28%).  Grade 3 
non-hematological AEs were nausea,  febrile neutrope-
nia (FN),  fatigue,  and rash,  of which nausea was the 
most frequent (n = 10,  24%).  FN was never observed 
more than once in the same patient.  The other AEs 
were observed several times in some patients.  These 
AEs quickly improved with supportive therapies,  and 
B-R therapy was not discontinued.  Cytomegalovirus 
reactivation was observed in 7% (3/42) of the patients,  
but responded rapidly to antiviral drug therapy.
Discussion
Bendamustine produced high response rates and 
durable responses in both LGBCL and MCL patients.  A 
retrospective analysis of patients receiving bendamus-
tine combined chemotherapy for r/r MCL has been 
reported from Spain.  In that report,  83% of patients 
were treated with B-R therapy,  and the ORR,  CR/CRu 
rate,  and median PFS were 84%,  53%,  and 16 months,  
respectively.  Only patients with CR/CRu had favorable 
PFS (median,  33 months) [9].  In a Japanese retrospec-
tive study of B-R therapy for r/r LGBCL and MCL,  
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Table 5　 Patient characteristics by cumulative dose of bendamustine
Cumulative dose of bendamustine
P value
≥720 mg/m2 (n=30) <720 mg/m2 (n=12)
Age,  n
　≥75 7 7 0.07
　<75 23 5
Sex,  n
　Male 16 8 0.51
　Female 14 4
Bulky mass (>7 cm),  n
　Yes 1 3 0.06
　No 29 9
Extranodal lesions ≥1,  n
　Yes 6 4 0.43
　No 24 8
Follicular lymphoma,  n
　Yes 21 8 1
　No 9 4
LDH (IU/L),  n
　>240 7 5 0.27
　≤240 23 7
Last regimen before B-R,  n
　Rituximab monotherapy 13 8 0.31
　Rituximab + chemotherapy 17 4
LDH,  lactate dehydrogenase; B-R,  bendamustine,  rituximab.
Table 6　 Response to the cumulative dose and RDI of bendamustine
ORR,  n (%) P value CR/CRu,  n (%) P value
Cumulative dose of bendamustine
　　≥720 mg/m2 30 (100) <0.05 19 (63) 1
　　<720 mg/m2 9 (75) 7 (58)
RDI of bendamustine
　　≥64.4% 21 (100) 0.23 13 (62) 1
　　<64.4% 18 (86) 13 (62)
ORR,  overall response rate; CR,  complete response; CRu,  complete response unconfirmed; RDI,  relative dose intensity.
Kawaguchi et al.  reported that the ORR,  CR/CRu rate,  
and 2-year PFS and OS rates were 81.1%,  39.6%,  
59.7% and 74.9%,  respectively [10].  In a prospective 
phase II clinical trial for r/r LGBCL and MCL (BRB 
study),  the ORR,  CR/CRu rate,  and median PFS were 
94%,  71%,  and 18 months,  respectively [11]; the max-
imum number of cycles of B-R therapy in that study was 
four.  Furthermore,  Sakai et al.  reported the efficacy of 
B-R therapy for r/r follicular lymphoma (n = 37).  In this 
prospective study,  the median number of cycles of B-R 
therapy was 5 (range 1 to 6),  and approximately half of 
the patients completed 6 cycles.  The ORR was 91.9% 
(95% CI,  78.1 to 98.3),  with a CR rate of 86.5% (95% 
CI,  71.2 to 95.5).  The 3-year PFS and OS rates were 
70.9% (95% CI,  52.3 to 83.3) and 88.9% (95% CI,  73.1 
to 95.7).  The dose of bendamustine was 240 mg/m2 per 
cycle in their study [12].  Although our study was retro-
spective,  the ORR,  CR/CRu rate,  and median PFS 
were 93%,  62%,  and 39 months,  respectively; these 
results were better than those of other retrospective 
studies and consistent with those of prospective studies.  
Furthermore,  the median PFS and OS of several factors 
were “not reached” in subgroup analyses,  and B-R ther-
apy demonstrated durable clinical responses in patients 
with these factors.  Two reasons why our study had a 
favorable outcome despite its retrospective nature may 
have been that the patients in our study were more 
likely to be using B-R as a second-line therapy and 
fewer patients were refractory.
The FLIPI is an index widely used to predict the out-
comes of patients with FL.  The risk factors in this equa-
tion include age,  clinical stage,  number of nodal 
lesions,  low hemoglobin level,  and high LDH [8].  In 
our study,  high LDH and the presence of extranodal 
lesions were identified as significant factors for predict-
ing poor PFS and OS.  A cumulative bendamustine dose 
of 720 mg/m2 or more seemed to contribute to favor-
able PFS and OS.  It is notable that the cumulative dose 
of bendamustine has been identified as a prognostic 
factor for PFS and OS in B-R therapy.  Ohmachi et al.  
reported that bendamustine monotherapy was less 
effective in patients with < 3 cycles than in those with ≥ 3 
cycles [13].  The dose of bendamustine was 240 mg/m2 
per cycle in their study,  and such that the cumulative 
dose of three cycles was 720 mg/m2.  In another study,  
Matsumoto reported the efficacy of RBD (rituximab,  
bendamustine,  dexamethasone) therapy for LGBCL 
(n = 27) and MCL (n = 6).  The ORR was 88% (29/33) 
with 58% (19/33) of patients showing CR/CRu.  The 
3-year PFS and OS rates were 75.5% and 88% respec-
tively.  The dose of bendamustine was 180 mg/m2 per 
cycle,  and the OS of the group treated with 5 
(= 900 mg/m2) or 6 cycles was significantly prolonged 
compared with that of the group treated with 4 
(= 720 mg/m2) or fewer cycles (p = 0.033,  univariate 
analysis) [14].  These results are consistent with ours.  
Furthermore,  we investigated the RDI of bendamustine 
in patients with LGBCL and MCL treated with B-R 
therapy.  To the best of our knowledge,  this is the first 
report to evaluate the RDI and clinical outcomes in 
patients with r/r LGBCL and MCL treated with B-R 
therapy.  There was no significant relationship between 
the clinical outcomes and the RDI of bendamustine.  It 
has been reported that a high RDI is a favorable factor 
for PFS and OS in patients with diffuse large B-cell lym-
phoma treated with R-CHOP (cyclophosphamide,  
doxorubicin,  vincristine,  prednisolone,  and ritux-
imab) [15 , 16].  However,  increasing the RDI is not 
related to improvements in PFS,  OS,  and ORR in 
patients with LGBCLs,  such as follicular lymphoma,  
treated with R-CHOP [17].  LGBCLs progress slowly 
because of the slow growth rate of lymphoma cells.  
Therefore,  administering the target dose may be more 
important than continuing dosing schedule.
A retrospective study of 9395 LGBCL patients regis-
tered between 2006 and 2013 through the SEER-
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Table 7　 Adverse events in 42 patients treated with B-R therapy
Events
Any grade Grade 3 Grade 4
n % n % n %
Hematological AEs
　Lymphopenia 40 95 19 45 10 24
　Neutropenia 36 86 13 31 10 24
　Thrombocytopenia 24 57 2 5 1 2
　Anemia 20 48 2 5 0 0
Non-hematological AEs
　Nausea 30 71 10 24 0 0
　Constipation 22 52 0 0 0 0
　Diarrhea 7 17 1 2 0 0
　Vomiting 6 20 0 0 0 0
　Fatigue 16 38 2 5 0 0
　Rash 8 19 1 2 0 0
　Alopecia 1 3 0 0 0 0
　Infusion-related reaction 12 28 0 0 0 0
　Febrile neutropenia 4 9 4 9 0 0
AE,  adverse event.
Medicare-linked database analyzed differences in infec-
tious disease profiles of case treated with (n = 1,239) and 
without bendamustine (n = 8,156) [18].  In that report,  
the hazard ratios for bacterial pneumonia,  cytomegalo-
virus reactivation,  herpes virus infection,  and pneu-
mocystis pneumonia were significantly higher in the 
bendamustine combination regimen than in the 
non-bendamustine combination regimen [18].  It has 
been reported that bendamustine causes sustained 
lymphopenia,  especially for CD4+ T cells [19].  In our 
analysis,  the incidence of grade 3/4 lymphopenia was 
high.  Based on the abovementioned data,  antibiotic 
and antiviral drug prophylaxis was performed in all our 
patients; thus,  development of these severe infections 
was rare.  Our study confirmed the importance of pro-
phylaxis with antibiotic and antiviral drugs during B-R 
therapy.
The incidence of FN in our study was 9%,  which is 
higher than that reported previously.  In our study,  FN 
tended to increase after 4 cycles of B-R therapy (1 
patient in the 3rd cycle,  3 patients each in the 4th 
through 6th cycles),  with a high relative incidence in 
outpatients.  However,  after the onset of FN,  broad- 
spectrum antibiotics and G-CSF were administered 
immediately in all patients,  resulting in early improve-
ment.  FN could be adequately managed by such a sup-
portive care.  The incidence of severe anemia and 
thrombocytopenia was low,  and similar to that in other 
phase II clinical trials.  Grade 3 nausea,  fatigue,  and 
rash were observed,  but were improved by supportive 
care in almost all patients.  There was no discontinua-
tion of B-R therapy due to these AEs.
The major reason for administering a low cumula-
tive bendamustine dose (< 720 mg/m2) was prolonged 
neutropenia (n = 5,  42%).  Thus,  the use of G-CSF to 
ameliorate prolonged neutropenia could enable a 
cumulative dose of bendamustine ≥ 720 mg/m2.  This is 
expected to lead to an improved prognosis,  a better 
ORR,  and a deeper response.  The inability to adminis-
ter a cumulative dose of bendamustine up to 720 mg/m2 
reflected diseases exacerbation and,  not surprisingly,  
correlated with a poor prognosis.
In conclusion,  we investigated the efficacy and safety 
of B-R therapy for r/r LGBCL and MCL in clinical prac-
tice.  B-R therapy was highly effective and well tolerated.  
A cumulative dose of bendamustine ≥ 720 mg/m2 
appeared to contributed to improved PFS and OS.  
However,  our study had the following limitations: (i) 
we did not reconfirm the histology of each lymphoma,  
(ii) the study was retrospective,  and (iii) the number of 
patients was limited.  Therefore,  further studies are 
needed.
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